Unstable Angina

Current Concepts of Pathogenesis and Treatment

John A. Ambrose, MD; George Dangas, MD

During the past 15 years, we have learned an enormous amount about the pathogenesis and treatment of unstable angina. In most cases of unstable rest angina, the pathogenesis is a mural thrombus formation on a ruptured or eroded atherosclerotic plaque. However, any process that acutely changes the supply-demand ratio (decreased supply or increased demand in the presence of a decrease in supply) can precipitate the clinical presentation of unstable angina. Standard acute antithrombotic drug therapy is effective in decreasing progression to infarction. Newer agents (low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibitors) are more effective, and their use is evolving. Percutaneous intervention and bypass surgery can reduce symptoms and multiple hospitalizations, in most cases without a decrease in the long-term mortality rate. Because the cost of hospitalization is extremely high and the clinical presentation and outcome are heterogeneous, better triage methods are required.

Unstable angina is a common cardiovascular disorder, accounting for at least 500,000 to 750,000 hospital admissions per year in the United States. Although in the era of modern medical therapy the in-hospital mortality rate is low (<3%) in randomized trials, in-hospital morbidity is still considerable.

DEFINITION OF UNSTABLE ANGINA

The term unstable angina was first used in the early 1970s to define a condition referred to in earlier publications as preinfarction angina, crescendo angina, acute coronary insufficiency, or intermediate coronary syndrome. There have been several classifications of unstable angina. In the commonly used Braunwald classification, unstable angina was defined first in terms of its severity. Class I included the new onset of severe or accelerated angina of less than 2 months’ duration without rest pain. Class II included rest pain during the preceding month but not within the last 48 hours. Class III included angina at rest within the preceding 48 hours. Unstable angina was further classified into the clinical circumstances under which it occurred, the amount of cardiac medication being taken at presentation, and whether electrocardiographic changes were present (Table 1). Although the large number of categories might detract from its practical utility in clinical cardiology practice, results of 2 prospective studies validate the major subdivisions of this classification in its ability to risk stratify patients who are admitted to the hospital.

As unstable angina implies, the condition is intermediate between stable angina and myocardial infarction (MI). This seems appropriate because unstable angina is a common forerunner to MI; in some studies, most patients report that in the week before infarction, they experienced chest discomfort consistent with unstable angina.

PATHOGENIC MECHANISMS IN UNSTABLE ANGINA

In the mid-1980s, several researchers suggested that unstable angina was linked to non-Q and Q wave MI, and that these conditions represented a spectrum of disease in which plaque disruption or fissuring led to thrombus formation and the acute coronary syndrome. Intracoronary thrombus formation was thought to explain the pathogenesis in most patients with unstable angina. As opposed to MI
with ST-segment elevation in which the thrombus was usually occlusive, the thrombus in unstable angina was mural and did not result in total coronary occlusion in 80% to 90% of patients (Figure 1).13 Non-Q wave infarction is positioned between the other 2 conditions because there was more frequent total occlusion of the culprit artery than in unstable angina but less than in Q wave MI.19,15

Nearly all pathologic evidence in acute syndromes originates from autopsy studies.18 Because short-term mortality of unstable angina is low, autopsy data in unstable angina represent a highly select population. Aside from these, pathologic material in unstable angina has been obtained mainly from atheromatous plaque that is excised during directional atherectomy of the culprit lesion.17,18 This analysis is subject to sampling error because only a portion of the plaque is removed. Accordingly, our understanding of its pathogenesis derives mainly through other methods, including angiography, angioscopy, and biochemical studies.

### Thrombus Formation in Unstable Angina

Results of angiographic studies10,19,20 suggest that intracoronary thrombus formation or a complex lesion (ulcerated or irregular plaque) is found in 50% to 80% of culprit lesions, particularly if the presentation is rest pain. Serial angiograms performed before and after an episode of unstable angina, without an intervening coronary intervention, have shown progression of coronary artery disease in about 75% of patients.21,22

Recently, Dangas et al23 correlated coronary morphologic features of the culprit lesion to the Braunwald classification. There were significant (P<.05) positive correlations between severity of the unstable angina presentation and presence of an intracoronary thrombus or complex lesion. Results of angiographic studies24 also indicate that intracoronary thrombus or yellow plaque is found in most unstable culprit arteries but infrequently in stable angina. The thrombus in unstable angina has been characterized as grayish-white and presumably platelet-rich, whereas in MI it was red.25 Because the coronary artery is usually totally occluded in MI, this red thrombus is rich in fibrin and red blood cells, superimposed on the platelet component and potentiated by stasis of blood flow. Although angiography is commonly used to detect thrombus, it has low sensitivity relative to angioscopy.26,27 However, angiography is relatively specific (80%-90%) for the detection of thrombus or a complex lesion.26,27 Small thrombi or mural thrombi that do not cause luminal irregularity probably cannot be detected angiographically. In conclusion, thrombus formation on a presumed disrupted, fissured, or eroded plaque is the most common pathophysiological mechanism in unstable angina, particularly when the presentation is that of acute rest pain. However, it is unrealistic to assume that thrombus formation can explain all unstable presentations. For patients without rest pain, there are less convincing data that thrombus is the predominant cause. In our opinion, these patients require further evaluation.

### Other Pathogenic Mechanisms in Unstable Angina

Other mechanisms might explain the clinical syndromes of unstable angina. Inflammation has been implicated. Inflammation plays a role in plaque rupture, contributing to destabilization of the fibrous cap of so-called vulnerable plaques by secretion of matrix metalloproteinases.28 Results of directional atherectomy analysis of culprit lesions in unstable angina show a higher percentage of the excised plaque area infiltrated by inflammatory cells compared with stable angina. One difficulty with understanding the role of inflammation is the interrelationship between thrombus formation and inflammation. Tissue factor is found more commonly in unstable vs stable plaques, and results of histopathologic analysis29,30 of atherectomy specimens show a strong association between macrophage infiltration and tissue factor localization. Local expression of tissue factor by macrophages can lead to activation of the coagulation cascade. Furthermore, activation of platelets might lead to inflammatory reactions at the site of vascular lesions.31 Another link between inflammation and thrombosis might be lipoprotein(a). Recent data32 suggest that lipoprotein(a), which is considered atherosclerotic and thrombogenic, also colocalizes in macrophage-rich areas in unstable plaques. At the molecular
level, the apolipoprotein A portion of the lipoprotein(a) molecule has been shown to be responsible for macrophage chemotraction.

Another potential nonthrombotic mechanism for unstable angina might be smooth muscle cell proliferation. In lesions without angiographic evidence of thrombus, some patients have an abundant proliferation of smooth muscle cells on directional atherectomy analysis of excised plaque similar to that found in restenotic lesions. Again, excluding a role for thrombus is difficult because one third of lesions had thrombus demonstrated on tissue analysis, although the angiogram suggested no thrombus. Furthermore, thrombus might be a potent stimulus for smooth muscle cell proliferation, along with cytokines or growth factors released from inflammatory cells or other stimuli, including infectious agents like Chlamydia pneumoniae and cytomegalovirus. Smooth muscle cell proliferation without thrombus might play a role in unstable angina in the restenotic lesion. Restenotic lesions do not usually contain thrombus, yet their presentation might be that of rest pain even with enzyme level elevation, indicating non–Q wave MI (Figure 2).

Finally, occasionally there are patients who present with rest ischemia and ST-segment elevation in whom vasospasm on an angiographically normal-appearing vessel is present. However, most patients with so-called Prinzmetal variant angina have fixed and severe atherosclerotic lesions with superimposed thrombus.

Pathogenic vs Ischemic Mechanisms in Unstable Angina

In general, the pathogenesis of coronary disease relates to the slow or rapid progression of atherosclerosis. Ischemic mechanisms, on the other hand, reflect an imbalance between myocardial blood supply and oxygen demand. As physicians, we evaluate patients with silent or clinical ischemia. In unstable angina, transient decreases in blood supply or even small increases in myocardial demand in the presence of a new significant lesion might precipitate ischemic manifestations of the disease, namely, angina, by altering the balance. Transient decreases in supply related to intracoronary thrombus formation with spontaneous lysis or embolization, or transient increases in vasomotor tone, might lead to rest pain. Activated platelets release several vasoactive substances that, in the presence of endothelial dysfunction (impaired vasodilation), can result in vasoconstriction at or distal to the lesion and a transient decrease in blood flow. Although a thrombus is usually present to explain or contribute to decreases in blood supply, any process (thrombotic or otherwise) that significantly perturbs this balance can lead to unstable angina.

NATURAL HISTORY AND PROGNOSIS

Natural History of Unstable Angina

Before the era of modern medical therapy, a few studies assessed clinically long-term outcomes. In 1973, Gages et al followed up patients with recurrent rest pain in the hospital with ischemic ST and T wave changes. At 1 year their mortality was 43%, whereas at 10 years it was 81%. In 1985, Mulcahy et al reported the natural history in patients who were not treated with angioplasty or bypass surgery. One-year mortality was 8% to 10%, with a 12% to 14% incidence of nonfatal infarction. With antithrombotic drug therapy, there have been significant reductions of 50% to 70% in the incidence of in-hospital death or MI in placebo-controlled randomized trials. However, even in the most recent randomized trials, the incidence of MI in the hospital or at short-term follow-up during aspirin or antiocoagulant drug therapy was about 5% to 10%, whereas the incidence of refractory angina was 10% to 20%.

Prognosis in Unstable Angina

Several factors have been identified that increase morbidity or mortality, including clinical presentation, electrocardiographic changes at rest, enzymatic evidence of necrosis or inflammation, certain angiographic findings, and Holter evidence of ischemia (Table 2).

A panel of experts convened by the Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute developed guidelines, published in 1994, that defined factors associated with increased risk of infarction or death and the determinants of significant coronary disease (Table 3 and

<table>
<thead>
<tr>
<th>Table 2. Factors Associated With Increased Morbidity or Mortality in Unstable Angina*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical presentation14,52</td>
</tr>
<tr>
<td>Prolonged rest pain, recurrent rest pain in the hospital, postinfarction rest pain, heart failure, or hypotension with chest pain</td>
</tr>
<tr>
<td>Electrocardiographic changes45-46</td>
</tr>
<tr>
<td>ST-segment deviation ≥0.5 mm, left bundle branch block, or symmetrical T inversions</td>
</tr>
<tr>
<td>Enzyme evidence of myocardial necrosis or inflammation27,48-47</td>
</tr>
<tr>
<td>Elevated troponin T or I, creatine kinase–MB, or C-reactive protein result</td>
</tr>
<tr>
<td>Angiographic findings48-49</td>
</tr>
<tr>
<td>Significant left main coronary artery disease, left ventricular dysfunction intracoronary thrombus, or a complex-appearing lesion</td>
</tr>
<tr>
<td>Holter evidence of ischemia50,51</td>
</tr>
<tr>
<td>Silent ischemia of ≥60 min on 24-h monitoring after hospital admission</td>
</tr>
</tbody>
</table>

*Each of these factors usually compared with the absence of the clinical presentation, electrocardiographic change, enzyme level increase, etc.
Table 3. Likelihood of Significant CAD in Patients With Symptoms Suggesting Unstable Angina

<table>
<thead>
<tr>
<th>High Likelihood</th>
<th>Intermediate Likelihood</th>
<th>Low Likelihood</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any of the following features:</td>
<td>Absence of high-likelihood features and any of the following:</td>
<td>Absence of high-likelihood and intermediate-likelihood features:</td>
</tr>
<tr>
<td>Known history of CAD</td>
<td>Definite angina: men ≥60 y or women ≥70 y</td>
<td>Chest pain, probably not angina</td>
</tr>
<tr>
<td>Definite angina: men ≥60 y or women ≥70 y</td>
<td>Probable angina: men ≥60 y or women ≥70 y</td>
<td>One risk factor but not diabetes</td>
</tr>
<tr>
<td>Hemodynamic changes or ECG changes with pain</td>
<td>Probably not angina in diabetic or non-diabetic patients with ≥2 other risk factors†</td>
<td>T wave flat or inverted &lt;1 mm in leads with dominant R waves</td>
</tr>
<tr>
<td>Variant angina</td>
<td>Extracardiac vascular disease</td>
<td>Normal ECG findings</td>
</tr>
<tr>
<td>ST increase or decrease ≥1 mm</td>
<td>ST depression of 0.05 to 1.00 mm</td>
<td></td>
</tr>
<tr>
<td>Marked symmetrical T wave inversion in multiple precordial leads</td>
<td>T wave inversion ≥1 mm in leads with dominant R waves</td>
<td></td>
</tr>
</tbody>
</table>

*CAD indicates coronary artery disease; ECG, electrocardiographic.
†CAD risk factors include diabetes, smoking, hypertension, and elevated cholesterol level. Reprinted with permission from Clinical Practice Guideline, Unstable Angina (AHCPR) Publication 94-0602: Agency for Health Care Policy and the NHLBI, 1994.

Table 4. Short-term Risk of Nonfatal Myocardial Infarction in Patients With Symptoms Suggesting Unstable Angina

<table>
<thead>
<tr>
<th>High Risk</th>
<th>Intermediate Risk</th>
<th>Low Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any of the following features must be present:</td>
<td>No high-risk features but must have any of the following:</td>
<td>No high- or intermediate-risk features but may have any of the following:</td>
</tr>
<tr>
<td>Prolonged ongoing (&gt;20 min) rest pain</td>
<td>Rest angina now resolved but not low likelihood of CAD</td>
<td>Increased angina frequency, severity, or duration</td>
</tr>
<tr>
<td>Pulmonary edema</td>
<td>Rest pain (&lt;20 min or relieved with rest or nitroglycerin therapy)</td>
<td>Angina provoked at a lower threshold</td>
</tr>
<tr>
<td>Angina with new or worsening mitral regurgitation murmurs</td>
<td>Angina with dynamic T wave changes</td>
<td>New-onset angina within 2 wks to 2 mos</td>
</tr>
<tr>
<td>Angina with S or r waves</td>
<td>Nocturnal angina</td>
<td>Normal or unchanged ECG findings</td>
</tr>
<tr>
<td>Angina with hypotension</td>
<td>New-onset CCSC III or IV angina in past 2 wk but not low likelihood of CAD</td>
<td></td>
</tr>
<tr>
<td>Age &gt;65 y</td>
<td>Q wave or ST depression ≥1 mm in multiple leads</td>
<td></td>
</tr>
</tbody>
</table>

*CAD indicates coronary artery disease; CCSC, Canadian Cardiovascular Society Class; ECG, electrocardiographic. Reprinted with permission from Clinical Practice Guideline, Unstable Angina (AHCPR) Publication 94-0602: Agency for Health Care Policy and the NHLBI, 1994.

Table 4). Because these were consensus-based rather than evidence-based guidelines, no prospective validation had been attempted at the time of publication. Preliminary data from an analysis of 69 emergency department visits for chest pain in Olmstead County, Minnesota, suggest that the Agency for Health Care Policy and Research assessment of high, intermediate, and low risk for subsequent coronary events could stratify patients evaluated in this setting. Other studies are in progress to attempt to prospectively validate these findings.

MEDICAL THERAPY IN UNSTABLE ANGINA

Antianginal Therapy

As mentioned previously, ischemia, whether silent or clinically evident, is related to an imbalance between myocardial blood supply and oxygen demand. Antianginal drugs, including organic nitrates, β-adrenergic blocking agents, and calcium channel blockers, are commonly prescribed. Results of several studies indicate that, used alone or in combination, they reduce ischemia. However, there are few data that use of these drugs reduces the incidence of subsequent MI. Only in meta-analysis has it been shown that use of β-adrenergic blocking agents significantly reduces subsequent MI. This reduction was small (13%) compared with a much larger benefit afforded by antithrombotic drug therapy.

Ordinarily, in the setting of rest pain, β-adrenergic blocking agents and organic nitrates (usually intravenous nitroglycerin) are prescribed and titrated until heart rate is 50 to 60 beats/min and blood pressure is well controlled. Calcium channel blockers are generally not first-line therapy. In patients with a contraindication to β-adrenergic blocking agents or with refractory pain, calcium channel blockers can be used. In patients with Prinzmetal angina and rest pain, calcium channel blockers and nitrates are first-line therapy; β-adrenergic blocking agents should not be prescribed because they can potentiate spasm.

Antithrombotic Drug Therapy

The modern era of antithrombotic drug therapy in unstable angina began in 1983 with publication of the Veterans Administration Cooperative Study, showing the beneficial effects of short-term aspirin therapy on reducing the in-hospital and 1-year event rates compared with placebo. Previous studies with anticoagulant drugs in unstable angina were flawed by initial study design or by treatment violations. In placebo-controlled randomized trials of aspirin in doses of 75 to 1300 mg/d, all dosages were effective in reducing the incidence of MI or death by about 50% to 70% (Table 5).
Intravenous, unfractionated heparin therapy has also been compared against or in combination with aspirin therapy.30-42 Results of some studies indicated that heparin therapy was superior to aspirin therapy in reducing cardiac events, particularly refractory angina, whereas others suggested it was at least as good as aspirin therapy. However, with heparin therapy alone, Theroux et al39 found rebound unstable angina within the first 12 hours of cessation of heparin administration. This rebound phenomenon (also seen with other antithrombin agents) was prevented by pretreatment with aspirin. It is now commonplace to treat patients early with a combination of aspirin and heparin unless there is a contraindication. Usually patients receive low-dose aspirin (<324 mg/d) and intravenous heparin with a partial thromboplastin time of about 60 to 75 seconds. Administration of the agents is continued for 3 to 5 days until stabilization or an intervention is performed.

New Antithrombotic Approaches in Unstable Angina

Recently, 3 different classes of drugs have been extensively tested in randomized trials: low-molecular-weight heparin, direct thrombin inhibitors, and various intravenous inhibitors of the platelet glycoprotein (GP) IIb/IIIa receptor. The impetus for the development of these newer drugs was, in part, related to the incomplete protection afforded by aspirin and unfractionated heparin. There has been no consistent decrease in the incidence of refractory angina with aspirin or heparin therapy, and MI or death, although reduced, has not been completely prevented.

Low-Molecular-Weight Heparin.

Low-molecular-weight heparins have potential advantages over unfractionated heparin, including a more predictable anticoagulant effect with a higher ratio of anti-factor Xa to anti-factor IIa, thus inhibiting the generation of thrombin at a higher point in the coagulation cascade. They also require no monitoring of anticoagulation, are administered subcutaneously, and are resistant to inhibition by activated platelets. Results of several randomized clinical trials66 demonstrated that low-molecular-weight heparins were at least comparable to unfractionated heparin in preventing deep vein thrombosis after surgery. The Fragmin During Instability in Coronary Artery Disease (FRISC) study67 evaluated therapy with combination aspirin and subcutaneous dalteparin sodium vs aspirin in unstable angina or non–Q wave MI. Dalteparin was given subcutaneously twice daily for up to 6 days, followed by a single injection daily for the next 35 to 45 days vs placebo injections. In 1506 randomized patients, there was a significant 6% reduction in this combined end point of death or infarction in the dalteparin group vs the aspirin group. The control group did not receive standard unfractionated heparin. In the Fragmin in Unstable Coronary Artery Disease (FRIC) study,68 a direct comparison with unfractionated heparin was carried out. Dalteparin therapy was as effective as unfractionated heparin therapy during short-term management of unstable angina or non–Q wave infarction. Prolonged treatment (>45 days) did not confer any additional benefit over aspirin therapy alone. In the Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q Wave Coronary Events (ESSENCE) trial,44 3171 patients with rest angina or non–Q wave infarction were randomized to receive low-molecular-weight heparin (enoxaparin sodium, 1 mg/kg) subcutaneously twice daily vs continuous intravenous unfractionated heparin for 48 hours to a maximum of 8 days, with a reduction in the primary end point of death or MI at 14 days from 19.8% to 16.6%, respectively (P<.02). These statistically significant reductions in composite end points were maintained at 30 days and at 1 year.69 A similar positive result for enoxaparin therapy in unstable angina was recently shown in the Thrombolysis in Myocardial Infarction (TIMI) IIb trial.70 Why the results of the ESSENCE and TIMI XIB trials were positive whereas the FRISC study67 showed no added benefit for low-molecular-weight heparin therapy is speculative, but might be related to trial design or to intrinsic differences between low-molecular-weight heparin compounds (ie, the higher ratio of anti–factor Xa to anti–factor IIa of enoxaparin to dalteparin).

Direct Thrombin Inhibitors.

Unlike heparins, direct thrombin inhibitors do not require a cofactor (anti-thrombin III) for their effect. There are also no circulating inhibitors, and they are not inactivated by platelet factor IV. They are also effective against circulating and clot-bound throm-
bin. Because they are resistant to binding by endothelial cells and other plasma proteins, direct thrombin inhibitors more predictably prolong the partial thromboplastin time than does unfractionated heparin.

In the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb trial,12 142 patients with an acute syndrome were randomly assigned to 72 hours of therapy with intravenous heparin or hirudin. More than 8000 patients had no ST elevation and a diagnosis of unstable angina or non–Q wave MI. The primary end point of death or nonfatal infarction or reinfarction at 30 days was insignificantly reduced by hirudin therapy from 9.8% to 8.9%. In patients without ST elevation, the results were even less impressive. On the other hand, at 24 hours there were fewer adverse events during hirudin infusion. There was no increase in the incidence of serious or life-threatening bleeding complications, although moderate bleeding was increased with hirudin therapy. It is unclear why results of this trial were not positive at 30 days for hirudin, but it has been suggested that, like most thrombin inhibitors, rebound might occur once drug administration is stopped. In addition, hirudin therapy might not effectively block thrombin generation. Therefore, there is the potential for a small amount of thrombin to be generated in an area hidden from the effects of hirudin that might lead to subsequent thrombus formation.71

Platelet Glycoprotein IIb/IIIa Receptor Antagonists. In unstable angina, the thrombus is platelet rich, and interfering with platelet aggregation seems to be the most important strategy for reducing clinical events. This is suggested by several lines of evidence: (1) biologic and rheologic evidence of thrombus formation without total coronary occlusion, (2) angiographic data showing white thrombi or ulcerated plaques in unstable angina vs red thrombi and total occlusion in MI, (3) the effects of aspirin use in decreasing adverse events in unstable angina and the lack of efficacy of using thrombolytic agents, and (4) the importance of platelet activation and aggregation after arterial vessel wall injury in the process of subacute stent thrombosis.

In the past few years, a new class of drug has been developed that interferes with the final common pathway of platelet aggregation—exposure of the GPIIb/IIIa receptor on the platelet (Figure 3).72 Nearly all randomized trials in the short-term management of unstable angina have involved these competitive antagonists, which are small peptide or nonpeptide molecules that bind the receptor and block fibrinogen binding.

In 1998, data from 4 large, randomized trials66-68,73 (>17 000 patients) were published (Table 6). All involved infusion of one of these agents for 48 hours or longer. In 3 studies heparin was given in the placebo group, and in the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM PLUS) trial, the treatment group also received heparin. In the Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy (PURSUIT) study, heparin was given only at the physician’s discretion, although nearly all patients received it. The PRISM PLUS trial had an arm that received only the nonpeptide GPIIb/IIIa inhibitor (tirofiban hydrochloride), whereas another arm received tirofiban and heparin. All placebo patients received aspirin. Results of 3 of the 4 trials were positive, with a significant difference for their primary end point between the study drug and control groups. In early 1999, tirofiban and eptifibatide were approved by the Food and Drug Administration for use in patients with unstable angina or non–ST-segment elevation infarction. Because the agents are more expensive than conventional unfractionated heparin and might also increase bleeding complications, it remains unclear in which patients these agents should be used. Until the cost-benefit ratio of the newer strategies can be determined, it makes sense to limit their use in the short-term management of unstable angina to patients at high risk for adverse events. Thus, patients in the high-risk category by American Heart Association/American College of Cardiology guidelines should be included. Patients with refractory angina or recurrent rest pain after MI should also be treated with these drugs. Perhaps patients with rest pain and evidence of myocardial necrosis (elevated creatine kinase–MB or an elevated troponin) should also be considered candidates for therapy.

ANGIOGRAPHY

Role and Timing of Angiography

Because the diagnosis of unstable angina is clinical, it is not uncommon that some patients might have other

Figure 3. The platelet glycoprotein (GP) IIb/IIIa integrin is the final common pathway for platelet aggregation, which in turn is a major determinant of intracoronary thrombus formation. Effective GPIIb/IIIa inhibition is a new treatment modality for unstable angina. ADP indicates adenosine diphosphate; AA, arachidonic acid; TxA2, thromboxane A2; and IV, intravenous.
TIMI IIIB trial,75 patients with un- 
giography in unstable angina? In the 
interventional therapy, or bypass 
fore, coronary angiography helps 
therapy is likely to benefit. There-
tricular dysfunction that surgical 
disease or signifi-
19%. Angiography also identifies left 
went angiography, the incidence 
main coronary disease or signifi-
previous history of coronary disease un-
patient who present with chest pain of 
noncardiac causes for their clinical 
complaints of chest pain. In most 
advantages76 of unstable angina, nor-
oral or insignificant coronary dis-
case is found in 10% to 20% of pa-
tients. Even in TIMI IIIB,77 in which 
patients with rest pain and new elec-
trocardiographic changes or a pre-
vious history of coronary disease under-
went angiography, the incidence of 
significant disease was 11% to 
19%. Angiography also identifies left 
main coronary disease or signifi-
cant multivessel disease and left ven-
tricular dysfunction that surgical 
therapy is likely to benefit. There-
fore, coronary angiography helps 
identify which form of therapy is 
most beneficial (ie, medical therapy, 
interventional therapy, or bypass 
surgery).

When is the proper time for an-
giography in unstable angina? In the 
TIMI IIIB trial,77 patients with un-
stable angina or non–Q wave infarction 
(the latter represented about one 
third of the trial) were randomized to 
(1) an invasive strategy whereby 
cardiac catheterization was per-
formed less than 48 hours after pre-
sentation or (2) an early conserva-
tive strategy whereby only patients 
with recurrent ischemia at rest, a 
positive predischarge stress thal-
lium test result, or recurrent signifi-
cant angina after discharge would 
undergo catheterization. In more 
than 1400 patients at 6 weeks, there 
was no significant difference be-
tween invasive (98% catheteriza-
tion rates) and conservative (64% 
catheterization rates) strategies in the 
incidence of the primary end point of 
death or MI. The incidence of by-
pass surgery or angioplasty in the 
conservative group vs the invasive 
group was 50% vs 63%.

Until recently, the TIMI IIIB 
trial was the only randomized com-
parison of these 2 strategies. The 
high rate of catheterization and re-
vascularization in the conservative 
strategy might have been responsi-
ble for lessening the benefit of an 
invasive strategy, as carried out in 
TIMI IIIB. Recently, the Veterans Af-
airs Non–Q-Wave Infarction Strate-
gies in Hospital (VANQWISH) 
trial78 randomized 920 patients 
within 24 to 72 hours of experienc-
ing an acute non–Q wave MI to in-
vase vs conservative approaches 
using criteria similar to that of 
TIMI IIIB. Catheterization rates in 
VANQWISH were lower in the con-
servative arm (29% at 30 days) than 
were rates in TIMI IIIB (64% at 42 
days); rates in the invasive strategy 
arm were similar to those in TIMI 
IIIB (>95%). Revascularization 
procedures in VANQWISH were 44% in 
the invasive arm vs 33% in the con-
servative arm. Mortality or nonfa-
tal MI (the primary end point) or 
mortality alone was significantly 
higher in the invasive strategy at hos-
pital discharge, at 1 month, and at 
1 year (P < .05 for all). In this trial, 
the difference in mortality between 
the 2 strategies was primarily re-
lated to the higher mortality rate for 
coronary bypass surgery in the in-
vasive arm (11.6%) than in the con-
servative arm (3.4%).

Similar data questioning the role 
of early catheterization and revas-
cularization in unstable angina and 
non–Q wave infarction was re-
ported in the Organisation to Assess 
Strategies for Ischaemic Syndromes 
(OASIS) Registry.77 Nearly 8000 con-
secutive patients with unstable 
angina or MI without ST-segment el-
evation were prospectively recruited 
from 95 hospitals in 6 countries and 
followed up for 6 months. Overall, 
48% underwent angiography and 
33% underwent a revascularization 
procedure. Hospitals with vs with-
out catheterization facilities had 
higher catheterization (60% vs 30%) 
and revascularization (40% vs 20%) 
rates during follow-up. There was no 
significant difference in cardiovas-
cular mortality or MI among coun-
tries, and a lower mortality rate 
was present in hospitals without 
vs with routine catheterization facili-
ties (10.6% vs 12.5%; P = .05) at 6 
months.

How does one interpret these 
new data, which question the role of 
an early invasive approach in un-
stable angina? Surely, the data cast 
some doubt on the usual practice of 
early angiography commonly per-
formed in many countries, such as 
the United States. However, there are 
limitations to these newer studies. 
The surgical mortality rate in 
VANQWISH was high, and multives-
sel disease was routinely managed 
with bypass surgery rather than con-

---

**Table 6. Large Randomized Trials of Intravenous Glycoprotein IIb/IIa–Blocker Therapy in the Acute Management of Unstable Angina**

<table>
<thead>
<tr>
<th>Trial†‡</th>
<th>Patients, No.</th>
<th>Drug Therapy</th>
<th>Randomized Group</th>
<th>Outcome (Primary End Point)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRISM48</td>
<td>3231</td>
<td>48 h of IV tirofiban</td>
<td>Heparin + ASA</td>
<td>Significant decrease in CEP at 48 h from 5.6% to 3.8% with tirofiban, P = .01</td>
</tr>
<tr>
<td>PRISM PLUS47</td>
<td>1915</td>
<td>48 h of IV tirofiban‡</td>
<td>Heparin + ASA</td>
<td>Significant decrease in 7-d death/MI from 9.3% with heparin to 4.9% with tirofiban + heparin, P = .007, and a decrease in CEP from 17.9% to 12.9%, P = .004</td>
</tr>
<tr>
<td>PARAGON73</td>
<td>2282</td>
<td>72 h of IV lamifiban</td>
<td>Heparin + ASA</td>
<td>No decrease in 30-d end point of MI/death</td>
</tr>
<tr>
<td>PURSUIT48§</td>
<td>10 948</td>
<td>≤72 h of IV eptifibatide§</td>
<td>(Heparin) + ASA</td>
<td>Significant decrease in 30-d MI/death from 15.7% to 14.2% with eptifibatide, P = .04</td>
</tr>
</tbody>
</table>

*All trials also contained some patients with non–Q wave MI. IV indicates intravenous; ASA, aspirin; CEP, composite end point; MI, myocardial infarction; LD, low dose; and HD, high dose.†See the “Antithrombotic Drug Therapy” section for expansion of the trial names. PARAGON indicates Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.

§Heparin was optional.

‡If intervention was performed, the study drug could be infused for an additional 24 h (PURSUIT) or 48 h (PRISM PLUS) after the procedure.

†See the “Antithrombotic Drug Therapy” section for expansion of the trial names. PARAGON indicates Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.

§Heparin was optional.

‡If intervention was performed, the study drug could be infused for an additional 24 h (PURSUIT) or 48 h (PRISM PLUS) after the procedure.
Based on analysis of the Agency for Health Care Policy and Research guidelines of the Agency for Health Care Policy and Research, patients with unstable angina classes, and all should undergo invasive evaluation during hospitalization. Based on guidelines of the Agency for Health Care Policy and Research, patients with intermittent or persistent rest pain, and those with high-risk clinical features, e.g., a history of MI or revascularization, left ventricular failure, or hypotension, should be catheterized as early as possible after hospitalization. The pros and cons of invasive vs conservative approaches will continue to be debated until proper studies can be performed that include cost analyses and long-term clinical follow-up.

### Triage of Low-Risk Patients

Based on analysis of the Agency for Health Care Policy and Research clinical guidelines and perhaps the use of a sensitive, prognostic marker of myocardial necrosis, e.g., troponin T or I, triage can be performed safely in patients with unstable angina. This could limit the need for hospitalization in some patients, thus decreasing medical costs. Particularly in patients without high-risk clinical findings, including noninvasive tests (abnormal electrocardiographic finding or elevated troponin test result), evidence of significant heart failure, or left ventricular dysfunction, a trial of medical therapy might be appropriate. Although a large percentage of patients who are hospitalized with unstable angina will have 1 or more of these adverse signs or symptoms, triage performed in an emergency department or chest pain unit might be used to safely discharge some of these low-risk patients, even without hospitalization. Furthermore, the use of exercise testing or radionuclide imaging in this setting has been proposed and is being tested in several centers in the United States and abroad. The use of exercise testing to triage stabilized patients with unstable angina has previously been reported in small groups of patients.

### PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY AND CORONARY INTERVENTION

Coronary angioplasty has been used in unstable angina since the early 1980s. Dividing unstable patients into those who stabilized before angioplasty, those who were refractory, and those who underwent angioplasty during early postinfarction angina, data from the late 1980s and early 1990s indicated a high complication rate in refractory and postinfarction angina, with a slightly lower success rate compared with patients already stabilized. In comparison, studies during this same period in angioplasty in stable angina showed higher success rates and lower complication rates than all 3 groups of patients with unstable angina (Table 7). In the 1990s, use of adjunctive agents like abciximab (ReoPro, c7E3 Fab; Centocor Inc, Malvern, Pa), in addition to intra-coronary stents, has markedly increased success rates and decreased short-term complications. Angiographic success can now be achieved in many laboratories in more than 95% of lesions. Patients with significant multivessel disease can be revascularized in a single setting, or the culprit lesion can be intervened on early and the remaining lesions at a later date.

Before the abciximab era, there was much enthusiasm for using intracoronary thrombolytic agents during intervention for unstable angina. Results of several uncontrolled studies suggested benefit in short-term closure or with high-risk procedures. To ascertain whether there was a role for prophylactic urokinase therapy during angioplasty in unstable angina, the Thrombolysis and Angioplasty in Unstable Angina (TAUSA) trial was performed. This randomized, multicenter, double-masked, placebo-controlled trial ascertained whether intracoronary urokinase therapy improved the short-term results of angioplasty and decreased the inhospital complication rate. The major findings of the trial in nearly 500 randomized patients were a higher short-term closure rate in patients treated with urokinase and a significantly higher composite clinical end point (MI, bypass surgery, or ischemia) compared with the placebo group. As a result of this trial and the equally dismal results of systemic or intracoronary thrombolytic therapy in the short-term management of unstable angina, emphasis has turned to the role of platelet activation and the use of newer and more powerful antiplatelet agents to prevent complications during percutaneous intervention.

### Table 7. Angioplasty in Unstable Angina

<table>
<thead>
<tr>
<th>Patient Status (Study Years)</th>
<th>Patients, No.</th>
<th>Success, %</th>
<th>Death</th>
<th>MI</th>
<th>CABG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initially stabilized (1986-1992)</td>
<td>1036</td>
<td>89</td>
<td>0.3</td>
<td>5.1</td>
<td>5.8</td>
</tr>
<tr>
<td>Refractory (1987-1990)</td>
<td>1438</td>
<td>85</td>
<td>1.3</td>
<td>6.3</td>
<td>6.8</td>
</tr>
<tr>
<td>Post-MI (1986-1990)</td>
<td>634</td>
<td>88</td>
<td>1.1</td>
<td>6.3</td>
<td>6.5</td>
</tr>
<tr>
<td>Stable angina (1985-1992)</td>
<td>10129</td>
<td>92</td>
<td>0.7</td>
<td>1.6</td>
<td>2.5</td>
</tr>
</tbody>
</table>

*Modified from de Feyer and Serruys.* These studies were performed before the routine use of glycoprotein IIb/IIIa antagonists and stents for intervention. MI indicates myocardial infarction; CABG, coronary artery bypass graft surgery.
Two large trials\(^87,88\) evaluated direct thrombin inhibitors during angioplasty, the Hirulog Angioplasty Trial and the Hirudin Trial (HELVETICA), which directly compared the newer agents with heparin. In the hirulog trial, bivalirudin (Hirulog, Biogen Inc, Cambridge, Mass) was given usually for 24 hours during and after angioplasty, whereas in the hirudin trial, patients received either intravenous hirudin for 24 hours during or after angioplasty or intravenous hirudin plus 3 days of subcutaneous hirudin after intervention. Results of the hirulog trial revealed no overall benefit for hirulog vs heparin therapy in diminishing adverse clinical events after angioplasty, although there was a significant reduction in adverse clinical events in patients undergoing intervention for postinfarction unstable angina with hirulog. In the HELVETICA trial, hirudin therapy decreased the incidence of adverse clinical events at 96 hours after angioplasty vs heparin therapy. However, at 7 months there was no difference between groups in the incidence of recurrent symptoms, clinical events, or restenosis rates.

### NEW ADJUNCTIVE ANTITHROMBOTIC THERAPY FOR INTERVENTION IN UNSTABLE ANGINA

#### Direct Thrombin Inhibitors

Two large trials\(^87,88\) evaluated direct thrombin inhibitors during angioplasty, the Hirulog Angioplasty Trial and the Hirudin Trial (HELVETICA), which directly compared the newer agents with heparin. In the hirulog trial, bivalirudin (Hirulog, Biogen Inc, Cambridge, Mass) was given usually for 24 hours during and after angioplasty, whereas in the hirudin trial, patients received either intravenous hirudin for 24 hours during or after angioplasty or intravenous hirudin plus 3 days of subcutaneous hirudin after intervention. Results of the hirulog trial revealed no overall benefit for hirulog vs heparin therapy in diminishing adverse clinical events after angioplasty, although there was a significant reduction in adverse clinical events in patients undergoing intervention for postinfarction unstable angina with hirulog. In the HELVETICA trial, hirudin therapy decreased the incidence of adverse clinical events at 96 hours after angioplasty vs heparin therapy. However, at 7 months there was no difference between groups in the incidence of recurrent symptoms, clinical events, or restenosis rates.

### Platelet Glycoprotein IIb/IIIa Receptor Antagonists

Several drugs of this kind have been evaluated (Table 8). The most impressive results\(^89\) with adjunctive therapy during intervention have been with the use of abciximab—the chimeric monoclonal antibody against the platelet GPIIb/IIIa receptor—a noncompetitive inhibitor of this receptor that remains on the platelet until the platelet is removed from the circulation. Furthermore, significant amounts of abciximab are still present in the circulation 7 to 10 days after administration.\(^90\) Thus, the platelet inhibitory effects are more prolonged compared with the competitive blockers after therapy is terminated. In addition, compared with the competitive blockers, abciximab binds to the GPIIb/IIIa receptor and the vitronectin receptor on smooth muscle cells and platelets.\(^91\) This latter receptor might be important in smooth muscle cell proliferation. However, unlike the synthetic, competitive inhibitors of the GPIIb/IIIa receptor, abciximab has the potential to elicit an antibody response, possibly because of its murine origin or its comparatively large size. Bleeding risk might also be higher because of the more prolonged inhibition of platelet function than with other compounds.

In the Evaluation of 7E3 for the Prevention of Ischemic Complications trial,\(^92\) a subgroup of nearly 500 patients with unstable angina was randomized. The composite 30-day end point of death, MI, or emergency revascularization was reduced by 62% in the bolus plus 12-hour infusion group vs the placebo group (4.5% vs 12.8%; \(P = .01\)). This reduction was even greater than that seen in the entire trial (62% vs 35% with abciximab). However, abciximab therapy increased bleeding. Because bleeding events were higher in smaller patients but efficacy was not affected by body size, a second trial was initiated to evaluate whether weight adjustment of the heparin administered with abciximab might retain efficacy while decreasing bleeding. In the Evaluation in PTCA to Improve Long-Term Outcome With Abciximab GPIIb/IIIa Blockade (EPİLOG) trial,\(^93\) such a result was obtained. In patients given weight-adjusted heparin plus abciximab, there were significant decreases in adverse end points without significant increases in bleeding rates compared with those given placebo. In the third reported study using abciximab in unstable patients, the Reduction of Recurrent Ischemia With Abciximab During Continuous ECG-Ischemia Monitoring in Patients With Unstable Angina Refractory to Standard Treatment (CAPTURE) trial\(^94\) randomized 1265 patients with refractory unstable angina after angiography to abciximab vs placebo therapy begun 18 to 24 hours before their scheduled intervention. Drug administration was continued until 1 hour after intervention. After an interim analysis of 1050 patients (1400 patients were randomized and 1265 were ultimately treated), the trial was stopped because efficacy was significantly enhanced with abciximab therapy. Infarction rates were lower in the abciximab group vs the placebo group before angioplasty (0.6% vs 2.1%; \(P = .03\)) and during angioplasty (2.6% vs 5.5%; \(P = .009\)). Bleeding was

![Table 8. GPIIb/IIIa Antagonists During Coronary Interventions*](image-url)

<table>
<thead>
<tr>
<th>Trial†</th>
<th>Patients, No.</th>
<th>Heparin Bolus</th>
<th>Agent</th>
<th>30-d End Point, %‡</th>
<th>Major Bleeding, %</th>
<th>6-mo End Point, %§</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPIC90</td>
<td>2099</td>
<td>10 000-12 000 IU</td>
<td>Abciximab</td>
<td>8.3</td>
<td>12.8</td>
<td>14</td>
</tr>
<tr>
<td>EPILOG83</td>
<td>2792</td>
<td>70 or 100 U/kg</td>
<td>Abciximab</td>
<td>5.2; 5.4</td>
<td>11.7</td>
<td>2; 3.5</td>
</tr>
<tr>
<td>CAPTURE84</td>
<td>1265</td>
<td>≤100 U/kg</td>
<td>Abciximab</td>
<td>11.3</td>
<td>15.9</td>
<td>3.8</td>
</tr>
<tr>
<td>IMPACT II85</td>
<td>4010</td>
<td>100 U/kg</td>
<td>Epifibatide</td>
<td>9.2; 9.9</td>
<td>11.4</td>
<td>5.1; 5.2</td>
</tr>
<tr>
<td>RESTORE86</td>
<td>2139</td>
<td>150 U/kg (≤10 000 U)</td>
<td>Tirofiban</td>
<td>8</td>
<td>10.5</td>
<td>5.3</td>
</tr>
</tbody>
</table>

* GP indicates glycoprotein; MI, myocardial infarction; and NA, not applicable.
† See the “New Adjunctive Antithrombotic Therapy for Intervention in Unstable Angina” section for expansion of trial names. EPIC indicates Evaluation of FE3 for the Prevention of Ischemic Complications.
‡ Death, MI, or urgent revascularization.
§ Death, MI, or any revascularization, except IMPACT II data (only death or MI).
¶ P < .05 vs placebo. Double entries signify 2 subgroups within the study who received GP116.
∥ By treatment, 9.1% received analysis (P = .05 vs placebo).
higher than in the EPILOG trial but less than in the Evaluation of 7E3 for the Prevention of Ischemic Complications trial.92

Other GPIIb/IIIa inhibitors have been studied. In the Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE)93 and Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis (IMPACT) II94 trials, the competitive GPIIb/IIIa agents tirofiban and eptifibatide, respectively, were used. Both trials demonstrated beneficial results vs placebo therapy, although they were not as significant as those seen with abciximab therapy. The less than optimal benefit seen in the IMPACT II trial with eptifibatide therapy might have been related to an insufficient dose of drug to effectively block the GPIIb/IIIa receptor. The inhibitory effects of eptifibatide on the receptor are strongly affected by plasma calcium levels. Use of citrates as an anticoagulant for platelet aggregation studies might have artificially overestimated the in vivo antplatelet effects of eptifibatide therapy in this trial because citrate binds calcium and reduces its plasma concentration.97

Thus, use of platelet GPIIb/IIIa blockers is indicated during coronary intervention in unstable angina. Because the best results have been shown with abciximab therapy, this agent is preferred whenever possible. However, the competitive GPIIb/IIIa blockers are also effective, and their use should be continued in patients in the catheterization laboratory for intervention who are already taking one of these agents. In patients previously exposed to abciximab, these other agents might also be preferable, although readministration of abciximab has been reported98 without a significant increase in adverse events over first-time use.

**Stenting in Unstable Angina**

Stents are commonly used in unstable angina, although no randomized trials, to our knowledge, have shown benefit in this group, per se. However, a recently published retrospective study99 has shown benefit for stents in unstable angina. With use of aspirin, ticlopidine, hydrochloride, or clopidogrel, and high-pressure inflations to ensure proper stent deployment, subacute thrombosis is now rare (<1%), even in unstable angina with complex or ulcerated lesions. That stenting is not prohibitive with thrombotic lesions has been seen in primary angioplasty studies of MI. Stenting might be preferable to percutaneous transluminal coronary angioplasty alone in this setting.100

**SURGICAL REvascularization IN UNSTABLE ANGINA**

Established indications for aorto-coronary bypass surgery include obstructive (>50%) left main coronary disease or 3-vessel disease with decreased left ventricular systolic function.101-104 These have been established from prospective, randomized trials that found surgery to be superior to medical therapy in stable and unstable patients. Two large, randomized trials105-108 of bypass surgery vs medical therapy in unstable angina have been performed. The Veterans Administration Cooperative Study randomized 468 patients. Although 3-year mortality was similar in both groups, patients with 3-vessel disease, alone and with decreased ventricular function (<50% ejection fraction), had a survival advantage with surgery. The high operative mortality and limited use of the internal thoracic artery as a bypass conduit limited the value of this study. Medical therapy was also suboptimal by today’s standards because antithrombotic drugs were not used. In the National Heart, Lung, and Blood Institute trial105,106 of bypass surgery vs medical therapy in unstable angina performed in the early 1970s, there was no benefit for surgery over medical therapy in the hospital or in the 1- and 2-year incidence of death or MI. The long-term results of both studies were clouded by the high crossover rate from medical therapy to bypass surgery, which was 31% at 2 years in the National Heart, Lung, and Blood Institute Study, and 34% in the Veterans Administration Study.

With preserved left ventricular function, the presence of significant left main stenosis still warrants surgery. However, the presence of 2- or 3-vessel disease is not an indisputable indication for surgery, and care should be individualized. Coronary anatomy with discrete lesions might favor interventional therapy, whereas multiple long lesions and total occlusions with good distal target vessels favor bypass surgery. There are no direct comparisons of surgical vs percutaneous revascularization exclusively in the setting of unstable angina. Recent large trials109,110 compared balloon angioplasty and surgical revascularization in patients with multivessel disease and, at most, mild left ventricular systolic dysfunction. Although the balloon angioplasty arm had higher rates of multiple interventions, both groups had similar intermediate mortality rates in all these multicenter studies. In most of these studies, unstable angina was present in few patients; analyses of this subgroup have not been published. The Bypass Angioplasty Revascularization Investigation (BARI)110 was the only trial to incorporate predominantly unstable angina patients (64% with unstable angina and 6% were postinfarction). Cumulative 5-year survival was 89.0% in the surgical arm and 86.3% in the angioplasty arm (P is not significant). The clinical syndrome on presentation was not reported as a contributor to differences in mortality or reinfarction rates. Subgroup analysis of the BARI trial showed a mortality benefit in diabetic patients treated with surgery vs angioplasty.

Despite reservations regarding the immediate postoperative course of unstable angina in patients undergoing aorto-coronary bypass surgery, long-term outcome seems favorable. Rahimtoola et al112 reported the 5- and 10-year actuarial survival of patients with unstable rest angina after MI to be 92% and 83%, respectively, similar to the survival of patients with unstable angina and recent infarction. Furthermore, 15-year survival of patients with unstable angina was similar to that of patients with stable angina (59% vs 55%, respectively).

**CONCLUSIONS**

Unstable angina is a common clinical syndrome in which the most im-
important pathogenic mechanism is an intracoronary platelet-rich thrombus on a disrupted, ulcerated, or eroded atherosclerotic plaque leading to partial coronary occlusion. Medical therapy is aimed at preventing total coronary occlusion (antithrombotic and anticoagulant drug therapy), reducing myocardial oxygen demands, and preventing vasospasm (nitrate, β-adrenergic blocking agent, and sometimes calcium channel blocker therapy). New antithrombotic drug approaches have been developed that seem somewhat more effective than standard antithrombotic drug therapy, but at a higher cost. Angiography is often performed and is useful in identifying patients in need of interventional therapy by percutaneous techniques or bypass surgery, although newer studies question its routine use. Furthermore, because this clinical diagnosis is so common and because of the enormous cost of hospitalization, strategies are being developed to better triage patients into those in whom a noninvasive approach would be appropriate vs those in whom the more aggressive approach is warranted.

Accepted for publication May 3, 1999. Reprints: John A. Ambrose, MD, Comprehensive Cardiovascular Center, Saint Vincent’s Hospital and Medical Center of New York, 153 W 11th St, New York, NY 10011 (jambrose@saintvincentsnyc.org).

REFERENCES


